Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
06:07pm, Wednesday, 29'th Apr 2026
NEW YORK, April 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the dis
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
06:05pm, Wednesday, 29'th Apr 2026
NEW YORK, April 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the s
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
06:03pm, Wednesday, 29'th Apr 2026
NEW YORK, April 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of th
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
05:50pm, Wednesday, 29'th Apr 2026
NEW YORK, April 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
07:30am, Tuesday, 28'th Apr 2026
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Cohen & Steers Quality Income Realty Fund: The REIT Wrapper Adds A Layer Most Yield Investors Miss
11:06am, Monday, 27'th Apr 2026
BLUF: RQI delivers 8.93% annualized distribution yield through a leveraged REIT portfolio — but the structure beneath that yield includes a 30% leverage layer, floating-rate exposure on 19% of borro
Cohen & Steers Announces the Retirement of Francis C. Poli, General Counsel & Corporate Secretary
09:00am, Monday, 27'th Apr 2026
Brian W. Heller to succeed Mr. Poli in 2027 NEW YORK, April 27, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that Francis C.
NYSE Content Update: SEC Chair Paul Atkins to Ring Opening Bell at NYSE
08:55am, Monday, 20'th Apr 2026
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 20, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the
Cohen & Steers: Q1 Resilience Holds Fort For Q2 Recovery
05:53pm, Friday, 17'th Apr 2026
Cohen & Steers, Inc. delivered resilient Q1 results despite late-quarter AUM declines driven by poor markets. CNS's focus on high-duration equity hybrids, real estate, and infrastructure makes it high
Cohen & Steers: A Beneficiary Of Challenges In Private Markets
04:13pm, Friday, 17'th Apr 2026
Cohen & Steers, Inc. remains a Buy, with public real estate focus and strong fund performance positioning it for renewed inflows as macro headwinds abate. CNS reported Q1 EPS of $0.79 on $144M revenue
Cohen & Steers, Inc. (CNS) Q1 2026 Earnings Call Transcript
12:31pm, Friday, 17'th Apr 2026
Cohen & Steers, Inc. (CNS) Q1 2026 Earnings Call Transcript
Cohen & Steers Reports Results for First Quarter 2026
04:18pm, Thursday, 16'th Apr 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended March 31, 2026. The earnings release along with the accompanying earnings pr
Cohen & Steers (CNS) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Thursday, 16'th Apr 2026
Cohen & Steers (CNS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
